Clinical trial
Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma…
NCT00250887 · University of Zurich, Other · Completed
Key facts
| NCT number | NCT00250887 |
|---|---|
| Title | Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research |
| Official title | A Phase II Open Label Study of the Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research |
| Lead sponsor | University of Zurich, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Glioblastoma |
| Intervention type | Drug |
| Interventions | Gefitnib |
| Enrollment | 22 |
| Start date | Jul 1, 2005 |
| Completion | May 1, 2007 |
| First posted | Nov 8, 2005 |
| Last update posted | Oct 23, 2007 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: